Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases.

Gilead’s primary areas of focus include: antivirals (such as HIV/AIDS and chronic hepatitis), cardiovascular conditions (such as pulmonary arterial hypertension and resistant hypertension) and respiratory diseases (such as influenza and cystic fibrosis).

Our portfolio of 11 marketed products includes a number of category firsts and market leaders, including Atripla® - the first single tablet regimen for HIV infection. Gilead scientists invented the anti-influenza drug Tamiflu® (oseltamivir), which is marketed globally by Hoffmann-La Roche. The company’s latest therapy, Letairis® (ambrisentan), was approved in June 2007 and is a once-daily oral treatment for pulmonary arterial hypertension (PAH). PAH is a progressive, life-threatening disease for which new therapies are urgently needed.